Skip to main content
. Author manuscript; available in PMC: 2015 Sep 15.
Published in final edited form as: J Neuroimmunol. 2014 Jun 27;274(0):71–77. doi: 10.1016/j.jneuroim.2014.06.021

Figure 1. STI1 expression increases with tumor progression.

Figure 1

(A) Representative Xenogen images of three mice 5, 12 and 19 days after tumor implantation. (B) Graph illustrating the tumor size of samples used for STI1 analysis; n=4 animals per group; * p < 0.05. (C) Western blot of normal brain (CTR) and brain tumors 1, 2 and 3 weeks after intracranial injection. All samples probed with anti-STI1 antibody showed a band at the expected molecular weight (66 kDa). (D) A two-week old GL261 glioma in a CX3CR1GFP mouse was immunolabeled with anti-STI1 antibody (red) demonstrating the expression of STI1 by tumor and GAMs (inset, arrow); nuclei were stained with DAPI (blue). Bar, 100 μm. Data is representative of two separate experiments.